MASI Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 14.91%. Masimo Corp.'s return on equity of -19.18% beat Boston Scientific Corp.'s return on equity of 12.46%.

Masimo Corp. has a consensus price target of $187.57, signalling upside risk potential of 31.02%. On the other hand Boston Scientific Corp. has an analysts' consensus of $126.48 which suggests that it could grow by 26.46%. Given that Masimo Corp. has higher upside potential than Boston Scientific Corp., analysts believe Masimo Corp. is more attractive than Boston Scientific Corp..

Masimo Corp. has a beta of 1.279, which suggesting that the stock is 27.874% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.581, suggesting its less volatile than the S&P 500 by 41.925%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Masimo Corp.'s net income of $53.7M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Boston Scientific Corp.'s PE ratio is 53.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.52x versus 7.72x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Clearpoint Neuro, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of -63.34%. Masimo Corp.'s return on equity of -19.18% beat Clearpoint Neuro, Inc.'s return on equity of -88.01%.

Masimo Corp. has a consensus price target of $187.57, signalling upside risk potential of 31.02%. On the other hand Clearpoint Neuro, Inc. has an analysts' consensus of $29.00 which suggests that it could grow by 83.43%. Given that Clearpoint Neuro, Inc. has higher upside potential than Masimo Corp., analysts believe Clearpoint Neuro, Inc. is more attractive than Masimo Corp..

Masimo Corp. has a beta of 1.279, which suggesting that the stock is 27.874% more volatile than S&P 500. In comparison Clearpoint Neuro, Inc. has a beta of 1.282, suggesting its more volatile than the S&P 500 by 28.204%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Clearpoint Neuro, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Clearpoint Neuro, Inc. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are larger than Clearpoint Neuro, Inc. quarterly revenues of $9.2M. Masimo Corp.'s net income of $53.7M is higher than Clearpoint Neuro, Inc.'s net income of -$5.8M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Clearpoint Neuro, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.52x versus 13.08x for Clearpoint Neuro, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integra LifeSciences Holdings Corp. has a net margin of 14.46% compared to Masimo Corp.'s net margin of -1.34%. Masimo Corp.'s return on equity of -19.18% beat Integra LifeSciences Holdings Corp.'s return on equity of -37.15%.

Masimo Corp. has a consensus price target of $187.57, signalling upside risk potential of 31.02%. On the other hand Integra LifeSciences Holdings Corp. has an analysts' consensus of $15.50 which suggests that it could grow by 28.74%. Given that Masimo Corp. has higher upside potential than Integra LifeSciences Holdings Corp., analysts believe Masimo Corp. is more attractive than Integra LifeSciences Holdings Corp..

Masimo Corp. has a beta of 1.279, which suggesting that the stock is 27.874% more volatile than S&P 500. In comparison Integra LifeSciences Holdings Corp. has a beta of 1.197, suggesting its more volatile than the S&P 500 by 19.711%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra LifeSciences Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Integra LifeSciences Holdings Corp. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Integra LifeSciences Holdings Corp. quarterly revenues of $402.1M. Masimo Corp.'s net income of $53.7M is higher than Integra LifeSciences Holdings Corp.'s net income of -$5.4M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Integra LifeSciences Holdings Corp.'s PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.52x versus 0.56x for Integra LifeSciences Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Merit Medical Systems, Inc. has a net margin of 14.46% compared to Masimo Corp.'s net margin of 7.22%. Masimo Corp.'s return on equity of -19.18% beat Merit Medical Systems, Inc.'s return on equity of 8.28%.

Masimo Corp. has a consensus price target of $187.57, signalling upside risk potential of 31.02%. On the other hand Merit Medical Systems, Inc. has an analysts' consensus of $104.73 which suggests that it could grow by 19.62%. Given that Masimo Corp. has higher upside potential than Merit Medical Systems, Inc., analysts believe Masimo Corp. is more attractive than Merit Medical Systems, Inc..

Masimo Corp. has a beta of 1.279, which suggesting that the stock is 27.874% more volatile than S&P 500. In comparison Merit Medical Systems, Inc. has a beta of 0.638, suggesting its less volatile than the S&P 500 by 36.238%.

Masimo Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merit Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Masimo Corp. pays -- of its earnings as a dividend. Merit Medical Systems, Inc. pays out -- of its earnings as a dividend.

Masimo Corp. quarterly revenues are $371.5M, which are smaller than Merit Medical Systems, Inc. quarterly revenues of $384.3M. Masimo Corp.'s net income of $53.7M is higher than Merit Medical Systems, Inc.'s net income of $27.8M. Notably, Masimo Corp.'s price-to-earnings ratio is 116.80x while Merit Medical Systems, Inc.'s PE ratio is 44.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Masimo Corp. is 4.52x versus 3.60x for Merit Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.